Granules India Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Published 25 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹21.3K Cr
Granules India expects continued strong growth in FY27, building on a 22% YoY growth in Q1 FY27 and similar growth trajectory in prior quarters. Granules India anticipates continued strong revenue growth, with 22% YoY growth in Q1 FY27 and similar growth trajectory expected for full FY27 (Page 6).
From Granules India's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Price
₹846
Market Cap
₹21.3K Cr
P/E Ratio
32.7
Revenue Rank
Margin Rank
How does Granules India rank in Pharmaceuticals & Biotechnology?
Compare Granules India against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Granules India — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.5K Cr, net profit ₹202 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 2- →Granules India expects continued strong growth in FY27, building on a 22% YoY growth in Q1 FY27 and similar growth trajectory in prior quarters.
- →Complex generics, now 50% of finished dosages (up from 39% a year ago), are a key growth driver with sustainable growth expected.
- →Europe is seen as a strong growth market with a positive upward trajectory due to increased demand for products filed in the past.
- →Controlled substance products are growing, with existing products expanding market share and 1-2 new controlled substance launches expected starting FY28.
- →Peptide CDMO business aims for a 5x revenue increase over 5 years, targeting $50 million revenue with 30%+ EBITDA margin mid-way in this journey.
- →Overall, Granules India is confident of maintaining gross margins and EBITDA growth with steady capex supporting expansion.
📈 Profitability & Margins
Rank 3- →Granules India anticipates continued strong revenue growth, with 22% YoY growth in Q1 FY27 and similar growth trajectory expected for full FY27 (Page 6).
- →EBITDA margins are expected to remain stable around 22%-23%, supported by improving product mix favoring complex generics (Page 6).
- →Operating profitability should benefit from gross margin expansion driven by complex generics and calibrated pricing actions amidst RM cost pressures (Page 6).
- →Medium-term growth is driven by complex generics, oncology launches, controlled substances, and expansion of peptide CDMO business (Pages 13-14, 4).
- →R&D investment remains steady at around 5.5%-6% of sales, underpinning future differentiated product launches (Page 14).
- →ROCE improved to 18% and expected to progress steadily with scaling of Genome Valley and peptide platform (Page 7).
- →Overall, Granules projects continued margin accretion and sustainable profitability growth through diversification and complex product portfolio (Pages 4, 14).
🏗️ Capital Expenditure Plans
Yes- →Capex in Q1 FY27 was INR 89 crores; Genome Valley major investment completed.
- →Total capex guidance for FY27 remains at INR 600 crores, with further investments in digitalization and modular growth projects.
- →Oncology investment plan: around INR 100 crores for intermediates and INR 200 crores for API side, spread over multiple years.
- →Expansion of peptide intermediate plant in India underway; equipment ordered to scale solid phase synthesis, purification columns, and lyophilization capacity.
- →Genome Valley facility adds about 40% to formulation capacity; currently under scale-up.
- →Focus on strategic investments to enhance complex generics, ADHD, controlled substances, and oncology portfolios.
- →Long-term opportunities being studied in nonsolid dosage areas but at exploratory stage, not committed.
💰 Fundraising & Capital Structure
No information- →The transcript does not mention any current or future plans for fundraising through debt or equity.
- →The company reports a healthy balance sheet with net debt at INR1,012 million in Q1 FY27, down from INR4,021 million at FY26 close, indicating a low debt level.
- →The net debt to EBITDA ratio stands at approximately 0.07x, effectively making the company nearly debt-free.
- →Management expresses comfort in funding growth, capacity expansions, and R&D from the existing financial position.
- →Capex guidance for FY27 is INR600 crores, with no indication of additional fundraising.
- →Management focus is on capital efficiency and conservative capital allocation, with dividend policy under internal review but no mention of new capital raising.
- →Overall, no explicit plans or announcements related to raising new debt or equity are disclosed.
📋 Order Book & Pipeline
No information- →Granules India Limited has about 23-24 ANDA filings still pending approval.
- →Of these, 9 products are pending facility approval.
- →Approximately 9 products are pending approvals, primarily due to IP-related issues.
- →An additional 5 products from the U.S. are still pending approval; some are IP-based while others await regulatory approval.
- →In the oncology segment, 2 ANDAs have been filed in the U.S. and Europe, with around 14 extensions of the same dossiers in various countries.
- →The company has 9 to 13 oncology products at various stages of development.
- →Controlled substances have 4-5 launches pending, with 1 to 2 expected in the next 1.5 to 2 years.
- →No new controlled substance launches are expected in FY27; growth will come from existing products.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Granules India Q1 FY27 results?
Granules India expects continued strong growth in FY27, building on a 22% YoY growth in Q1 FY27 and similar growth trajectory in prior quarters. Granules India anticipates continued strong revenue growth, with 22% YoY growth in Q1 FY27 and similar growth trajectory expected for full FY27 (Page 6).
What is Granules India share price analysis?
Granules India currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 32.7 with a market cap of ₹21,265 Cr. Investors should review the full earnings analysis for detailed insights.
Is Granules India planning capital expenditure?
Capex in Q1 FY27 was INR 89 crores; Genome Valley major investment completed.
Keep Granules India on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.